Exclusive: AstraZeneca and Vaxess developing skin patch mRNA vaccines for pandemic flu
AstraZeneca is developing a novel type of mRNA vaccine that can be administered as a shelf-stable skin patch instead of a shot, potentially making distribution and administration of pandemic vaccines easier, Endpoints News has learned.
The pharmaceutical giant is partnering with Boston biotech startup Vaxess, which could get up to $10.3 million from AstraZeneca in a joint effort to develop prototype vaccines for pandemic influenza, Vaxess told Endpoints in an exclusive interview. Those funds are part of a larger award worth up to $80 million from the Department of Defense that AstraZeneca could use to develop and test the vaccine through a Phase I/II clinical study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.